Aprea Therapeutics (NASDAQ:APRE) Receives “Buy” Rating from HC Wainwright

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 430.50% from the company’s previous close.

Aprea Therapeutics Stock Up 4.1 %

Shares of NASDAQ:APRE traded up $0.15 on Wednesday, reaching $3.77. The company had a trading volume of 4,084 shares, compared to its average volume of 47,214. The stock has a market capitalization of $20.49 million, a P/E ratio of -1.34 and a beta of 0.75. The stock has a 50-day moving average price of $3.35 and a 200 day moving average price of $3.46. Aprea Therapeutics has a twelve month low of $2.15 and a twelve month high of $8.85.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.11. The business had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.45 million. Aprea Therapeutics had a negative return on equity of 57.86% and a negative net margin of 1,029.50%. On average, sell-side analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Marc Duey sold 6,462 shares of the business’s stock in a transaction dated Friday, October 18th. The stock was sold at an average price of $4.58, for a total transaction of $29,595.96. Following the completion of the transaction, the director now owns 233,651 shares of the company’s stock, valued at approximately $1,070,121.58. The trade was a 2.69 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 12.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aprea Therapeutics stock. Stonepine Capital Management LLC acquired a new stake in Aprea Therapeutics, Inc. (NASDAQ:APRE) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 137,174 shares of the company’s stock, valued at approximately $558,000. Aprea Therapeutics accounts for 0.5% of Stonepine Capital Management LLC’s portfolio, making the stock its 21st biggest holding. Stonepine Capital Management LLC owned 2.53% of Aprea Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.